Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 441

1.

Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.

Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, Briganti A, Montorsi F.

Eur Urol. 2019 Nov 7. pii: S0302-2838(19)30825-5. doi: 10.1016/j.eururo.2019.10.026. [Epub ahead of print]

PMID:
31708296
2.

Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.

Fehniger JE, Berger AA, Juckett L, Elvin J, Levine DA, Zajchowski DA.

Gynecol Oncol. 2019 Nov 5. pii: S0090-8258(19)31561-6. doi: 10.1016/j.ygyno.2019.10.004. [Epub ahead of print]

PMID:
31703812
3.

Genomic Analysis Reveals Low Tumor Mutation Burden Which May be Associated with GNAQ/11 Alteration in a Series of Primary Leptomeningeal Melanomas.

Fortin Ensign S, Bollin K, Millis SZ, Hinds BR, Kosty M, Uchiyama C.

Pigment Cell Melanoma Res. 2019 Oct 30. doi: 10.1111/pcmr.12839. [Epub ahead of print]

PMID:
31663661
4.

Poor prognoses of open globe injuries with concomitant orbital fractures.

Gaier ED, Tarabishy S, Bayers C, Wolkow N, Gardiner M, Lefebvre DR, Grob S.

Orbit. 2019 Oct 28:1-10. doi: 10.1080/01676830.2019.1663881. [Epub ahead of print]

PMID:
31658857
5.

Novel PDGFRB rearrangement in multifocal infantile myofibromatosis is tumorigenic and sensitive to imatinib.

Hassan M, Butler E, Wilson R, Roy A, Zheng Y, Liem P, Rakheja D, Pavlick D, Young LL, Rosenzweig M, Erlich R, Ali SM, Leavey PJ, Parsons DW, Skapek SX, Laetsch TW.

Cold Spring Harb Mol Case Stud. 2019 Oct 23;5(5). pii: a004440. doi: 10.1101/mcs.a004440. Print 2019 Oct.

6.

Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.

Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.

Oncologist. 2019 Oct 16. pii: theoncologist.2019-0603. doi: 10.1634/theoncologist.2019-0603. [Epub ahead of print] Review.

PMID:
31619547
7.

TKI-resistant ALK-rearranged lung adenocarcinoma with secondary CTNNB1 p.S45V and tertiary ALK p.I1171N mutations.

Ouseph MM, Taber A, Khurshid H, Madison R, Aswad BI, Resnick MB, Yakirevich E, Ali SM, Patel NR.

Lung Cancer (Auckl). 2019 Aug 15;10:81-86. doi: 10.2147/LCTT.S212406. eCollection 2019.

8.

Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing.

Mikubo M, Seto K, Kitamura A, Nakaguro M, Hattori Y, Maeda N, Miyazaki T, Watanabe K, Murakami H, Tsukamoto T, Yamada T, Fujita S, Masago K, Ramkissoon S, Ross JS, Elvin J, Yatabe Y.

J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33409-4. doi: 10.1016/j.jtho.2019.09.081. [Epub ahead of print]

PMID:
31605798
9.

The Pan-Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA.

Disel U, Madison R, Abhishek K, Chung JH, Trabucco SE, Matos AO, Frampton GM, Albacker LA, Reddy V, Karadurmus N, Benson A, Webster J, Paydas S, Cabanillas R, Nangia C, Ozturk MA, Millis SZ, Pal SK, Wilky B, Sokol ES, Gay LM, Soman S, Ganesan S, Janeway K, Stephens PJ, Zhu VW, Ou SI, Lovly CM, Gounder M, Schrock AB, Ross JS, Miller VA, Klempner SJ, Ali SM.

Oncologist. 2019 Oct 11. pii: theoncologist.2018-0528. doi: 10.1634/theoncologist.2018-0528. [Epub ahead of print]

PMID:
31604903
10.

Genomic profiling of cell-free circulating tumor DNA in patients with colorectal cancer and its fidelity to the genomics of the tumor biopsy.

Li G, Pavlick D, Chung JH, Bauer T, Tan BA, Peguero J, Ward P, Kallab A, Bufill J, Hoffman A, Sadiq A, Edenfield J, He J, Cooke M, Hughes J, Forcier B, Nahas M, Stephens P, Ali SM, Schrock AB, Ross JS, Miller VA, Gregg JP.

J Gastrointest Oncol. 2019 Oct;10(5):831-840. doi: 10.21037/jgo.2019.05.05.

11.

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.

Robichaux JP, Elamin YY, Vijayan RSK, Nilsson MB, Hu L, He J, Zhang F, Pisegna M, Poteete A, Sun H, Li S, Chen T, Han H, Negrao MV, Ahnert JR, Diao L, Wang J, Le X, Meric-Bernstam F, Routbort M, Roeck B, Yang Z, Raymond VM, Lanman RB, Frampton GM, Miller VA, Schrock AB, Albacker LA, Wong KK, Cross JB, Heymach JV.

Cancer Cell. 2019 Oct 14;36(4):444-457.e7. doi: 10.1016/j.ccell.2019.09.001. Epub 2019 Oct 3.

PMID:
31588020
12.

Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.

Klempner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, Reddy P.

Oncologist. 2019 Oct 2. pii: theoncologist.2019-0244. doi: 10.1634/theoncologist.2019-0244. [Epub ahead of print]

PMID:
31578273
13.

Common Secondary Genomic Variants Associated With Advanced Epithelioid Hemangioendothelioma.

Seligson ND, Awasthi A, Millis SZ, Turpin BK, Meyer CF, Grand'Maison A, Liebner DA, Hays JL, Chen JL.

JAMA Netw Open. 2019 Oct 2;2(10):e1912416. doi: 10.1001/jamanetworkopen.2019.12416.

14.

Efficacy of PD-1 Blockade in Refractory Microsatellite-Stable Colorectal Cancer With High Tumor Mutation Burden.

Gong J, Robertson MD, Kim E, Fakih M, Schrock AB, Tam KW, Burugapalli B, Monjazeb AM, Hendifar AE, Hitchins M, Klempner SJ, Cho M.

Clin Colorectal Cancer. 2019 Sep 4. pii: S1533-0028(19)30282-8. doi: 10.1016/j.clcc.2019.08.001. [Epub ahead of print] No abstract available.

PMID:
31563511
15.

Homologous recombination in lung cancer, germline and somatic mutations, clinical and phenotype characterization.

Kadouri L, Rottenberg Y, Zick A, Hamburger T, Lipson D, Peretz T, Nechushtan H.

Lung Cancer. 2019 Nov;137:48-51. doi: 10.1016/j.lungcan.2019.09.008. Epub 2019 Sep 12.

PMID:
31542568
16.

Predictive and Pharmacodynamic Biomarkers of Response to the Phosphatidylinositol 3-Kinase Inhibitor Taselisib in Breast Cancer Preclinical Models.

Moore HM, Savage HM, O'Brien C, Zhou W, Sokol ES, Goldberg ME, Metcalfe C, Friedman LS, Lackner MR, Wilson TR.

Mol Cancer Ther. 2019 Sep 18. pii: molcanther.0284.2019. doi: 10.1158/1535-7163.MCT-19-0284. [Epub ahead of print]

PMID:
31534012
17.

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha P, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LG.

J Clin Invest. 2019 Oct 1;129(10):4276-4289. doi: 10.1172/JCI128227.

18.

PD-L1 Status and Survival in Patients With Lung Cancer-Reply.

Miller PG, Li G, Singal G.

JAMA. 2019 Aug 27;322(8):783-784. doi: 10.1001/jama.2019.9196. No abstract available.

PMID:
31454037
19.

Erratum to "Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib" [Lung Cancer, 108 (June 2017) 228-231].

Ou SI, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM.

Lung Cancer. 2019 Aug 22. pii: S0169-5002(19)30614-2. doi: 10.1016/j.lungcan.2019.08.013. [Epub ahead of print] No abstract available.

20.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples.

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA, Ross JS, Hartmaier RJ, Huang SA, Sun JX.

J Mol Diagn. 2019 Nov;21(6):1053-1066. doi: 10.1016/j.jmoldx.2019.06.011. Epub 2019 Aug 22.

Supplemental Content

Loading ...
Support Center